Cyclacel Pharmaceuticals (CYCC) announced that it expects to implement a 1-for-16 reverse stock split on its shares of common stock effective May 12, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L884.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYCC:
- Cyclacel Pharmaceuticals Enters Share Exchange Agreement
- Cyclacel Pharmaceuticals enters exchange agreement with Fitters
- Biotech Alert: Searches spiking for these stocks today
- Cyclacel Pharmaceuticals files to sell 35.18M shares of common stock for holders
- Cyclacel Pharmaceuticals Shifts Focus to Cancer Drug Development